EP1370573A2 - Inhibiteurs a faible poids moleculaire de serine-proteases presentant des radicaux polyhydroxyalkyle et polyhydroxycycloalkyle - Google Patents

Inhibiteurs a faible poids moleculaire de serine-proteases presentant des radicaux polyhydroxyalkyle et polyhydroxycycloalkyle

Info

Publication number
EP1370573A2
EP1370573A2 EP01969785A EP01969785A EP1370573A2 EP 1370573 A2 EP1370573 A2 EP 1370573A2 EP 01969785 A EP01969785 A EP 01969785A EP 01969785 A EP01969785 A EP 01969785A EP 1370573 A2 EP1370573 A2 EP 1370573A2
Authority
EP
European Patent Office
Prior art keywords
alkyl
phenyl
pyr
equal
cooh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP01969785A
Other languages
German (de)
English (en)
Inventor
Dieter Herr
Helmut Mack
Werner Seitz
Wilfried Hornberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG filed Critical Abbott GmbH and Co KG
Publication of EP1370573A2 publication Critical patent/EP1370573A2/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond

Definitions

  • the present invention relates to new amidines and guanidines, their preparation and their use as competitive inhibitors of trypsin-like serine proteases, particularly thrombin and the complement proteases Cls and Clr.
  • the invention also relates to pharmaceutical compositions which contain the compounds as active constituents, and to the use of the compounds as thrombin inhibitors, anticoagulants, complement inhibitors and as anti-inflammatory agents.
  • Characteristic of the new compounds is the linkage of a serine protease inhibitor - with amidine or guanidine function, with an alkyl radical with two or more hydroxyl functions, this alkyl radical being derived from sugar derivatives. In this case, several sugar building blocks or building blocks derived from sugar can also be linked to one another. This principle of coupling with sugar derivatives leads to orally active compounds.
  • Reducing sugars are sugars that are able to reduce Cu (II) ions in solution to Cu (I) oxide.
  • Reducing sugars include:
  • aldoses whether in open chain or cyclic form
  • triosen or tetraoses such as erythrose, threose or pentoses such as arabinose, xylose, rhamnose, fucose, ribose or hexoses such as glucose, mannose, galactose, 2-deoxy-D-glucose, etc.
  • Hydroxyketoses contain a H0-CH 2 -C0 group. Fructose or ribulose are examples of this.
  • Di-oligo- and polysaccharides which contain a hemiacetal such as lactose, melibiose, maltose, maltotriose, maltotetraose, altohexaose or cellulose oligomers such as cellobiose, cellotriose or dextranoligomers or pullulanoligomers or inulin oligomers etc.
  • Sugar derivatives and complex oligosaccharides which contain a hemiacetal such as, for example, glucuronic acid, galacturonic acid, 2-deoxy-D-glucose, 2-deoxy-2-fluoro-D-glucose, glucosamine, lM-acetyl-D-glucosamine oligomers of pectin, hyaluronic acid.
  • sugar derivatives are the sugar acids which are reacted with a terminal amine function of the inhibitor via the acyl function.
  • Thrombin belongs to the group of serine proteases and plays a central role as a terminal enzyme in the blood coagulation cascade. Both the intrinsic and the extrinsic coagulation cascade lead to the formation of thrombin from prothrombin over several amplification stages. The thrombin-catalyzed cleavage of fibrinogen to fibrin then initiates blood coagulation and platelet aggregation, which in turn increases thrombin formation by • binding platelet factor 3 and coagulation factor XIII and a whole series of highly active mediators.
  • thromboin formation and action are central events in the development of both white, arterial and red, venous thrombi and therefore potentially effective targets for pharmaceuticals.
  • thrombin inhibitors are able, independently of cofactors, to completely inhibit the effects of free thrombin as well as that bound to platelets. They can prevent thromboembolic events after percutaneous transluminal coronary angioplasty (PTCA) and lysis in the acute phase and serve as anticoagulants in the extracorporeal circulation (cardiopulmonary machine, hemodialysis). They can also be used in general for thrombosis prophylaxis, for example after surgery.
  • PTCA percutaneous transluminal coronary angioplasty
  • lysis in the acute phase and serve as anticoagulants in the extracorporeal circulation (cardiopulmonary machine, hemodialysis). They can also be used in general for thrombosis prophylaxis, for example after surgery.
  • Thrombin inhibitors are suitable for the therapy and prophylaxis of
  • thrombin inhibitors of the D-Phe-Pro-Arg type are known, for which good thrombin inhibition is described in vitro: WO9702284-A, W09429336-A1, W09857932-A1, W09929664-A1, US5939392-A, WO200035869-A1 , WO200042059-A1, DE4421052-A1, DE4443390-A1, DE19506610-A1, W09625426-A1, DE19504504-A1, DE19632772-A1, DE19632773-A1, W09937611-A1, W09937668-A1, WO9523605-A149, A19505705-A149, US9523705-A149 -A1, EP-669317-A1,
  • the activation of the complement system ultimately leads to the lysis of cells via a cascade of approx. 30 proteins. At the same time, molecules are released which, like C5a, can lead to an inflammatory reaction.
  • the complement system serves to ward off foreign bodies such as viruses, fungi, bacteria, cancer cells.
  • the activation in the different ways initially takes place via proteases. By activation, these proteases are in able to activate other molecules of the complement system, which in turn can be inactive proteases. Under physiological conditions, this system - like blood clotting - is under the control of regulatory proteins that counteract excessive activation of the complement system. In these cases, an intervention to inhibit the complement system is not advantageous.
  • the complement system overreacts, contributing to the pathophysiology of diseases.
  • a therapeutic intervention in the complement system by inhibiting or modulating the excessive reaction is desirable.
  • Inhibition of the complement system is possible at different levels in the complement system and by inhibiting different effectors.
  • the literature there are examples of inhibition of the serine proteases at the Cl level with the aid of the Cl esterase inhibitor as well as inhibition at the level of the C3 or C5 convertases with the aid of soluble complement receptor CR1 (sCRl), inhibition at the level of C5 with the help of antibodies, inhibition at the level of C5a with the help of antibodies or antagonists.
  • the tools used to achieve inhibition are proteins in the examples given above.
  • low-molecular substances are described which are used to inhibit the complement system.
  • Some proteases from the various activation routes are particularly suitable for inhibiting the complement system. From the class of thrombin-like serine proteases, these are the complement proteases Clr and Cls in the classic way, factor D and factor B in the alternative way and MASP I and MASP II in the MBL way. The inhibition of these proteases then leads to a restoration of the physiological control of the complement system in the diseases or pathophysiological conditions indicated above.
  • an activation of the complement system can be expected for every inflammatory disease that is associated with the immigration of neutrophil blood cells. It is therefore expected that in all of these diseases an improvement in the pathophysiological status will be achieved by inhibiting parts of the complement system.
  • complement is associated with the following diseases or pathophysiological conditions Reperfusion damage after ischemia; Ischemic conditions occur during, for example, operations with the aid of heart-lung machines; Operations in which blood vessels are generally pinched to avoid major bleeding; Myocardial infarction; thromboembolic stroke; Pulmonary thrombosis, etc .;
  • organ failure such as multiple organ failure or ARDS (adult respiratory distress syndrome);
  • Alzheimer's disease and other inflammatory neurological diseases such as myastenia graevis, multiple sclerosis, cerebral lupus, Guillain-Barre syndrome; meningitis; Encaphi1itiden; Systemic lupus erythematosus (SLE);
  • Rheumatoid arthritis and other inflammatory diseases of the rheumatoid group e.g. Behcet's syndrome; Juvenile Rheumatoid Arthritis;
  • kidney inflammation of different origins such as Glomerulonephritis, lupus nephriti;
  • FUT and FU derivatives are amidinophenol esters and amidinonaphthol esters, respectively, and are described as complement inhibitors (eg Immunology (1983), 49 (4), 685-91).
  • Inhibitors which inhibit Cls and / or Clr but do not inhibit factor D are desirable. The following should preferably not be inhibited: t-PA, plasmin.
  • Thrombin Reagent (Cat. No. '126 594, Boehringer, Mannneim, Germany)
  • test substance solution and 50 ul citrate plasma are incubated for 2 minutes at 37 ° C (CL8, ball type, Bender & Hobein, Kunststoff, FRG). Then 100 ⁇ l thrombin reagent (37 ° C.) is added. The time until the lump of fibrin is formed is determined. The EC ⁇ oo values indicate the concentration at which the thrombin time is doubled.
  • Substrate H-D-Phe-Pip-Arg-pNA2HCl (S-2238, Chromogenix, Mölndahl, Sweden)
  • the chromogenic test can be carried out in microtiter plates. 10 ⁇ l substance solution in DMSO are added to 250 ⁇ l buffer with thrombin (final concentration 0.1 NIH units / ml) and 5 minutes at 20 to
  • Venous blood from the cephalic vein of healthy drug-free test subjects is collected.
  • the blood is mixed 9 to 1 with 0.13 molar trisodium citrate.
  • Platelet-rich plasma PRP
  • PPP Platelet-poor plasma
  • PRP and PPP can be stored for 3 hours at room temperature in closed PE containers. The platelet concentration is measured with a cell counter and should be between 2.5 to 2.8-10 8 / ml.
  • the platelet aggregation is measured turbitrimetrically at 37 ° C. (PAP 4, Biodata Corporation, Horsham, PA, USA). Before thrombin is added, 215.6 ⁇ l of PRP are incubated with 2.2 ⁇ l of test substance for 3 minutes and then stirred at 1000 rpm for 2 minutes. At a final concentration of 0.15 NIH units / ml, 2.2 ⁇ l of thrombin solution lead to the maximum agregation effect at 37 ° C./1000 rpm. The inhibited effect of the test substances is determined by the aggregation rate (slope) of thrombin without
  • Color substrate test for Clr inhibition reagents Clr from human plasma, activated, two-chain form (purity: approx. 95% according to SDS gel). No foreign protease activity detectable.
  • Substrate Cbz-Gly-Arg-S-Bzl product no. : WBAS012, (PolyPeptide, D-38304 Wolfenbüttel, Germany)
  • the test is started by adding 50 ⁇ l of a 1.5 mmolar substrate solution in 30%
  • IC 50 required inhibitor concentration in order to reduce the amidolytic Clr activity to 50%.
  • inhibitor concentration serves as the basis for the calculation.
  • Reagents Cls from human plasma, activated, two-chain form (purity: approx. 95% according to SDS gel). No foreign protease activity detectable.
  • Substrate Cbz-Gly-Arg-S-Bzl
  • Product no . WBAS012, (PolyPeptide, D-38304 Wolfenbüttel, Germany)
  • test buffer which contains Cls with a final concentration of 0.013 U / ml and DTNB with a final concentration of 0.27 mM /. 1 Incubate for 10 minutes at 20 to 25 ° C. The test is started by adding 50 ⁇ l of a 1.5 mmolar substrate solution in 30% DMSO (final concentration 0.375 mmol / 1). After an incubation time of 30 minutes at 20 to 25 ° C., the absorbance of each well at 405 ⁇ m is measured in a two-beam microtiter plate photometer against a blank value (without enzyme).
  • IC 50 inhibitor concentration required in order to reduce the amidolytic Cls activity to 50%.
  • inhibitor concentration serves as the basis for the calculation.
  • VBS stock solution 2.875 g / 1 veronal; 1.875 g / 1 Na veronal;
  • Ca / Mg stock solution 0.15 M Ca ++, 1 M Mg ++ EDTA stock solution:.
  • GVBS ++ buffer Dilute Ca / Mg stock solution 1: 1000 in GVBS buffer
  • GVBS / EDTA buffer Dilute EDTA stock solution 1:10 in GVBS buffer
  • SRBC ⁇ chafserythrocytes
  • SRBC were washed three times with GVBS buffer. The cell number was then set to 5.00E + 08 cells / ml in GVBS / EDTA buffer. Amboceptor was added in a dilution of 1: 600 and the SRBC was sensitized with antibody by incubation for 30 min at 37 ° C. with agitation. The cells were then washed three times with GVBS buffer at 4 ° C., then taken up in GVBS ++ buffer and adjusted to a cell number of 5 ⁇ 10 8 .
  • Lysis approach - Inhibitors were used in various concentrations with human serum or serum of other species in suitable dilution (e.g. 1:80 for human serum; a dilution is suitable at which approximately 80% of the maximum lysis that can be achieved by serum is achieved ) in GVBS ++ for 10 min at 37 ° C ° in a volume of 100 ⁇ l.
  • suitable dilution e.g. 1:80 for human serum; a dilution is suitable at which approximately 80% of the maximum lysis that can be achieved by serum is achieved
  • SRBC sensitized SRBC in GVBS ++ were then added. After incubation for 1 hour at 37 ° C. with agitation, the SRBC were centrifuged off (5 minutes; 2500 rpm 4 ° C.). 130 ul of the cell-free supernatant was transferred to a 96-well plate. The evaluation was carried out by measuring at 540 nm against GVBS ++ buffer.
  • the absorption values at 540 n are used for evaluation.
  • Factor D plays a central role in the alternative way of the complement system. Because of the low plasma concentration of factor D, the enzymatic step of factor B cleavage by factor D represents the rate-determining step in the alternative way of complement activation
  • factor D is a target for the inhibition of the complement system.
  • the commercially available substrate Z-Lys-SBzl * HCl is converted by the enzyme factor D (literature: Kam, CM. Et al., J. Biol. Chem. 262, 3444-3451, 1987).
  • the cleaved substrate is detected by conversion with Ellmann's reagent.
  • the resulting product is detected spectrophotometrically.
  • the response can be followed online. This makes enzyme-kinetic measurements possible.
  • the test is carried out based on clinical tests. By additional activation using e.g. Zymosan or Cobra Venom factor, the test can be modified.
  • EGTA ethylenebis (oxyethylenenitrilo) tetracetic acid
  • Human serum was either purchased from various suppliers (eg Sigma) or obtained from test persons in the BASF Süd outpatient clinic. Guinea pig blood was obtained and diluted 2: 8 in citrate solution. Multiple batches were used with no apparent differences.
  • VBS stock solution 2.875 g / 1 veronal 1.875 g / 1 Na veronal 42.5 g / 1 NaCl
  • VBS stock solution 1 5 with water (Finn Aqua)
  • the erythrocytes from the guinea pig blood were washed several times by centrifugation (5 minutes; 1000 rpm) with GTB until the supernatant was clear. The cell number was set to 2 * 10 9 cells / ml. 2. Procedure: The individual batches were incubated for 30 minutes at 37 ° C. with agitation. The mixture was then stopped with 480 ⁇ l of ice-cold saline (physical saline) and the cells were centrifuged at 5000 rpm for 5 minutes. 200 ⁇ l of the supernatant were measured at 405 nm by transferring them into a microtiter plate and evaluating them in a microtiter plate photometer. Pipetting a (quantities in ⁇ l)
  • the OD values are used for evaluation.
  • test substances are dissolved in isotonic saline immediately before administration to awake Sprague Dawley rats.
  • the application volumes are 1 ml / kg for intravenous bolus injection into the tail vein and 10 ml / kg for oral administration, which is carried out by gavage.
  • blood samples are taken 1 h after oral administration of 21.5 mg-kg -1 or intravenous administration of 1.0 mg-kg -1 of the test substance or the corresponding vehicle (control).
  • the animals are anesthetized by ip application of 25% urethane solution (dose 1 g-kg -1 ip) in physiological saline.
  • the carotid artery is prepared and catheterized.
  • Thrombin time 100 ⁇ l citrate-treated plasma is incubated for 2 min • at 37 ° C. in a coagulometer (CL 8, Kugel-Typ, Bender & Hobein, Kunststoff, FRG). After the addition of 100 ⁇ l of prewarmed (37 ° C.) thrombin reagent (Boehringer Mannheim), the time until 20 to form a fibrin clot was determined.
  • test substances are dissolved in isotonic saline immediately before administration to watchful mongrel dogs.
  • the application volumes are 0.1 ml / kg for intravenous bolus injection and 1 ml / kg for oral administration, which is carried out by gavage. Before and 5, 10, 20, 30, 45, 60, 90,
  • the anti-F Ila activity (ATU / ml) and the concentration of the substance are determined by their anti-F Ha activity in the plasma by means of a chromogenic (S-2238) thrombin assay, calibration curves with r-hirudin and the test substance 5 were used.
  • the plasma concentration of the test substance is the basis for the calculation of the pharmacokinetic parameters: time of the maximum plasma concentration (T max), maximum plasma concentration; Plasma half-life, t 0 .s; Area under the curve (AUC); absorbed part of the test substance (F).
  • Ecarin clotting time 100 ⁇ l of citrated blood are incubated for 2 min at 37 ° C. in a coagulometer
  • PTT activated thromboplastin time
  • Thrombin time 100 ⁇ l citrate-treated plasma is incubated for 2 min at 37 ° C. in a coagulometer (CL 8, Kugel-Typ, Bender & Hobein, Kunststoff, FRG). After the addition of 100 ⁇ l of prewarmed (37 ° C.) thrombin reagent (Boehringer Mannheim), the time until a fibrin clot was formed was determined.
  • the present invention relates to peptidic and peptidomimetic substances, their production and their use as thrombin or complement inhibitors.
  • the invention relates to the use of these new substances for the production of thrombin inhibitors, complement inhibitors, specifically inhibitors of Cls and Clr.
  • the invention relates to the use of chemically stable substances of the general formula I, their tautomers, pharmacologically tolerable salts and prodrugs for the manufacture of medicaments for the treatment and prophylaxis of diseases caused by partial or complete inhibition, in particular selective inhibition, thrombin, or Cls and / or Clr.
  • A stands for H, CH 3 , H- (R A1 ) IA
  • radicals R A1 may be the same or different;
  • R B1 is H, CH 2 OH, C ⁇ _ 4 alkyl
  • R B2 is H, NH 2 , NH-COCH 3 , F, NHCHO
  • R B3 is H, C ⁇ _ 4 -alkyl, CH 2 -0-C ⁇ _ 4 alkyl, COOH, F ', NH-COCH 3 ,
  • CONH 2 R B4 is H, C ⁇ - 4 alkyl, CH 2 -0-C ⁇ _ 4 alkyl, COOH,
  • R D1 is H, C ⁇ _ 4 alkyl
  • R D2 is the same as bond or C 4 alkyl
  • R D4 is the same bond, C ⁇ _ 4 alkyl, CO, S0 2 , -CH 2 -CO
  • R E1 means H, -C 6 alkyl, C 3 _ 8 cycloalkyl, aryl (in particular phenyl or naphthyl), heteroaryl (in particular pyridyl, thienyl, imidazolyl, indolyl), C 3 _g-cycloalkyl with a fused-on phenyl ring, the the aforementioned radicals can carry up to three identical or different substituents from the group C 6 alkyl, OH, C 6 alkyl, F, Cl, Br;
  • R E1 furthermore means R E4 0C0-CH 2 - (R E4 is H, C ⁇ _ ⁇ 2 alkyl, C ⁇ _ 3 alkylaryl);
  • R E2 means H, -C 6 alkyl, C 3 _ 8 cycloalkyl, aryl (especially phenyl or naphthyl), heteroaryl (especially pyridyl, furyl, thienyl, imidazolyl, indolyl), tetrahydropyranyl, tetrahydrothiopyranyl, diphenylmethyl, dicyclohexyl 3 _ 8 -cycloalkyl with a fused-on phenyl ring, where the abovementioned radicals can carry up to three identical or different substituents from the group -C 6 alkyl, OH, 0 -C 6 alkyl, F, Cl, Br, CH (CH 3 ) OH, CH (CF 3 ) 2 ;
  • R E3 means H, -C 6 alkyl, C 3 _ 8 cycloalkyl, aryl (especially phenyl or naphthyl), heteroaryl (especially pyridyl, thienyl, imidazolyl, indolyl), C 3 _ 8 cycloalkyl with a fused phenyl ring, the the aforementioned radicals can carry up to three identical or different substituents from the group C 6 alkyl, OH, O 6 alkyl, F, Cl, Br;
  • R E1 and R E2 can be accessed via a
  • Bond may be linked to one another, - the groups mentioned under R E2 and R E3 may also be linked to one another via a bond;
  • R E2 also stands for C0R E5 (R E5 is OH, O-Cx-e-alkyl, OC ⁇ _ 3 alkylaryl), CONR E6 R E7 (with R E6 or R E7 being H, C ⁇ - 6 alkyl, Co- 3 -alkylaryl), R E6 R E 7.
  • E can also stand for D-Asp, D-Glu, D-Lys, D-Orn, D-His, D-Dab, D-Dap, D-Arg;
  • N- C (C ⁇ - 3 alkyl) 2 , CH (C ⁇ _ 3 alkyl), CHF, CHCl, CF 2 can be replaced;
  • R G2 H, C ⁇ -C 6 alkyl, aryl
  • R G4 H -CC 6 alkyl, C 3 _ 8 cycloalkyl, aryl (in particular
  • nK 0, 1, 2, 3;
  • Q ⁇ is equal to ' C 2 _6-alkyl, where up to two CH 2 groups can be replaced by 0 or S;
  • R ⁇ l is H, C ⁇ _ 3 alkyl, OH, O-C1-3 alkyl, F, Cl, Br;
  • R K2 is H, C1-3 alkyl, O-Ci-3 alkyl, F, Cl, Br;
  • X ⁇ is 0, S, NH, N-C ⁇ _ 6 alkyl
  • W ⁇ is CH or 'where in the latter
  • nK o, 1, 2;
  • R L1 is H, OH, 0-C 6 alkyl, O- (CH 2 ) o- 3 phenyl,
  • radicals R A1 can be identical or different;
  • R B3 AB can stand for
  • R B is H, CH 2 OH
  • R B2 is H, NH 2 , NH-COCH 3 , F
  • R B3 is H, CH 3 , CH 2 -0 -C 4 alkyl, COOH
  • R B4 is H, -CC 4 alkyl, CH-0 -C 4 -alkyl, COOH,
  • R B 6 are the same C ⁇ - 4 alkyl, phenyl, benzyl B7 B is H, C ⁇ _ 4 alkyl, phenyl, benzyl
  • R D1 is H, C ⁇ _ 4 alkyl
  • R D2 is the same as bond or C ⁇ _ 4 alkyl, R D3 equal
  • R D4 is the same bond, C ⁇ _ alkyl, CO, S0 2 , -CH 2 -CO
  • R E1 means H, Ci- ⁇ - alkyl, C 3 _ 8 -cycloalkyl, the abovementioned radicals up to three identical or different
  • R E2 means H, -C 6 alkyl, C 3 _ 8 cycloalkyl, aryl (in particular phenyl or naphthyl), heteroaryl (in particular pyridyl, furyl, thienyl), tetrahydropyranyl, diphenylmethyl, dicyclohexylmethyl, the aforementioned radicals can carry up to three identical or different substituents of the group Cx-g-alkyl, OH, 0-C ⁇ _ 6- alkyl, F, Cl, Br, CH (CF 3 ) 2 ;
  • R E3 means H, Ci-e-alkyl, C 3-8 cycloalkyl
  • R E2 furthermore stands for C0R E5 (R E5 equals OH, 0-C ⁇ _ 6 -alkyl, OC ⁇ _ 3 -alkylaryl), C0NR E6 R E7 (with R E6 or R E7 equals H, C ⁇ _ 6 -alkyl, Co- 3 - Alkylaryl), NR 6R E ; E can also stand for D-Asp, D-Glu, D-Lys, D-Orn, D-His, D-Dab, D-Dap, D-Arg;
  • n G 0.1;
  • R ⁇ i is H, C ⁇ - 3 alkyl, OH, OC 1-3 -alkyl, F, Cl, Br;
  • R K2 is H, C 1-3 alkyl, 0-C 1 _ 3 alkyl, F, Cl, Br;
  • R L1 is H, OH, 0 -C 5 alkyl, C0 2 -C 1 _ 6 alkyl.
  • Preferred compounds of the formula are preferred thrombin inhibitors
  • radicals R A1 can be the same or different.
  • R B3 is H, CH 3 , COOH
  • R B4 is H, CH 3 , COOH, CHO, in the latter case intramolecular acetal formation can occur kB 0.1
  • R E2 means H, -C 6 alkyl, C 3 _ 8 cycloalkyl, phenyl, diphenylmethyl, dicyclohexylmethyl, the abovementioned radicals having up to three identical or different substituents from the group C 4 alkyl, OH, 0-CH 3 , F, Cl can wear
  • the ring can be replaced by
  • R 1 is H, CH 3 , OH, 0-CH 3 , F, Cl;
  • X ⁇ is 0, S, NH, N-CH 3 ;
  • R Li is H, OH, C0 -C ⁇ - 6 alkyl.
  • the compounds of the formula are preferred as complement inhibitors
  • A stands for H, H- (R A1 ) iA
  • radicals R A1 can be the same or different.
  • R B3 AB can stand for
  • R B3 is H, CH 3 , COOH
  • R B4 is H, CH 3 , COOH, CHO, in the latter case intramolecular acetal formation can occur
  • R B6 is C 4 alkyl, phenyl, benzyl
  • B B7 is H 4 C 4 alkyl, phenyl, benzyl
  • R D1 equal to H, C ⁇ - 4 alkyl
  • R D2 is the same as bond or C ⁇ _ 4 alkyl
  • R D6 is H, CH 3
  • R D4 is bond, C 1 _ 4 -alkyl, CO, S0, -CH 2 -CO,
  • R E2 means H, C 6 alkyl, C 8 cycloalkyl, where the abovementioned radicals can carry up to three identical or different substituents from the group C 4 alkyl, OH, 0-CH 3 , F, Cl
  • the ring can be replaced by
  • n 0.1;
  • R ⁇ l is H, CH 3 , OH, 0-CH 3 , F, Cl;
  • X ⁇ is 0, S, NH, N-CH 3 ;
  • R Li is H, OH, C0 2 -C ⁇ - 6 alkyl.
  • the compounds of the formula are particularly preferred as thrombin inhibitors
  • radicals R A1 can be the same or different.
  • R E2 means H, -C 6 alkyl, C 3 _ 8 cycloalkyl, phenyl, diphenylmethyl, dicyclohexylmethyl;
  • the E component preferably has a D configuration
  • the G building block preferably having an L configuration:
  • R L1 is H, OH, C0 2 -C ⁇ _ 6 alkyl.
  • the compounds of the formula are particularly preferred as complement inhibitors
  • A stands for H, H- (R A1 ) iA
  • radicals R A1 can be the same or different.
  • R B3 AB stands for
  • R B3 is H, CH 3 , COOH
  • R B4 is H, CH 3 , COOH, CHO, in the latter case intramolecular acetal formation can occur
  • R B6 is C ⁇ _ 4 alkyl, phenyl, benzyl
  • B B7 is H, C 4 alkyl, phenyl, benzyl
  • R D4 is bond, C ⁇ _ 4 alkyl, CO, S0 2 , -CH 2 -CO, E stands for
  • R E2 means H, -C 6 alkyl, C ß -s-cycloalkyl, where the abovementioned radicals can carry up to three identical or different substituents from group F, Cl
  • R L1 equals H, OH.
  • Preferred A-B modules are:
  • C ⁇ _ x alkyl includes all straight-chain and branched alkyl chains with one to ⁇ carbon atoms.
  • C 3 _ 8 -cycloalkyl stands for carbocyclic saturated radicals with 3 to 8 carbon atoms.
  • aryl stands for carbocyclic aromatics with 6 to 14 carbon atoms, in particular for phenyl, 1-naphthyl, 2-naphthyl.
  • heteroaryl stands for five- and six-ring aromatics with at least one heteroato N, 0 or S, in particular for pyridyl, thienyl, furyl, thiazolyl, imidazolyl; two aromatic rings can also be fused, e.g. Indole, N-C ⁇ _ -Alkylindol, benzothiophene, benzothiazole, benzimidazole, quinoline, isoquinoline.
  • C x - y -alkylaryl stands for carbocyclic aromatics which are linked to the skeleton via an alkyl group with X, x + 1, ... y-1 or y C atoms.
  • the compounds of the formula I can be present as such or in the form of their salts with physiologically tolerated acids.
  • acids are: hydrochloric acid, citric acid, tartaric acid, lactic acid, phosphoric acid, methanesulfonic acid, acetic acid, formic acid, maleic acid, fumaric acid, succinic acid, hydroxysuccinic acid, sulfuric acid, glutaric acid, aspartic acid, pyruvic acid, benzoic acid and oxyacid, glucuronic acid, glucuronic acid, glucuronic acid acetylglycine.
  • the new compounds of formula I are competitive inhibitors of thrombin or the complement system, especially C ⁇ s , and further from C ⁇ r .
  • the compounds according to the invention can be administered orally or parenterally (subcutaneously, intravenously, intramuscularly, intraperitoneally, rectally) in the customary manner. It can also be applied with vapors or sprays through the nasopharynx.
  • the dosage depends on the age, condition and weight of the patient and on the type of application.
  • the daily dose of active ingredient per person is between approximately 10 and 2000 mg when administered orally and between approximately 1 and 200 mg when administered parenterally. This dose can be given in 2 to 4 single doses or once a day as a depot form.
  • the compounds can be used in the customary pharmaceutical application forms in solid or liquid form, for example as tablets, film-coated tablets, capsules, powders, granules, dragees, suppositories, solutions, ointments, creams or sprays. These are manufactured in the usual way.
  • the active ingredients can be processed with the usual pharmaceutical auxiliaries such as tablet binders, fillers, preservatives, tablet disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, retardants, antioxidants and / or propellants (see H. Sucker et al.: Pharmaceuticals Technology, Thieme-Verlag, Stuttgart, 1978).
  • the application forms thus obtained normally contain the active ingredient in an amount of 0.1 to 99% by weight.
  • Prodrugs mean compounds that are in vivo
  • these substances are prodrugs from which the free amidine / guanidine compounds are formed under in vivo conditions. If ester compounds are present in the compounds of the formula I, these compounds can act in vivo as prodrugs from which the corresponding carboxylic acids are formed.
  • Acetyl Acpc 1-aminocyclopentane-1-carboxylic acid
  • Ala Alanine b-Ala: b-Alanine (3-aminopropionic acid) on: Amidino amb: amidinobenzyl
  • Asp Aspartic Acid Aze: Azetidine-2-carboxylic acid
  • Boc tert. butyloxycarbonyl
  • Chg cyclohexylglycine
  • Gly Glycine Glu: Glutamic acid for: Füran guan: Guanidino urine: Hydroxyamidino
  • Ind-2-COOH indoline-2-carboxylic acid iPr: iso-propyl Leu: leucine
  • Me Methyl MPLC: medium pressure liquid chromatography
  • NBS N-bromosuccinimide
  • Ohi-2-COOH octahydroindole-2-carboxylic acid
  • Ohii-1-COOH octahydroisoindole-1-carboxylic acid
  • Ph Phenyl Phe: Phenylal nin
  • Phg phenylglycine
  • TEA trietylamine
  • TFA trifluoroacetic acid
  • Thz-2-COOH 1,3-thiazolidine-2-carboxylic acid
  • Thz-4-COOH 1,3-thiazolidine-4-carboxylic acid thioph: thiophene
  • 3-Tic 3-tetrahydroisoquinoline carboxylic acid TOTU: 0- (cyano-ethoxycarbonylmethylene) -amino-] - N, N, N ', N' -tetramethyluronium tetrafluoroborate Z: Benzy1oxycarbony1
  • the building blocks A-B, D, E, G and K are preferably constructed separately and used in a suitably protected form (see scheme I, use of orthogonal protective groups (P or P *) which are compatible with the synthetic method used).
  • L * is an amide, thioamide or nitile function at this stage of the synthesis, then this is converted into the corresponding amidine or hydroxyamidine function, depending on the end product sought.
  • Amidine syntheses for the benzidine, picolylamidine, thienyl amidine, furylamidine and thiazolylamidine compounds of structure type I starting from the corresponding carboxylic acid amides, nitriles, carboxylic acid thioamides and hydroxyamidines are described in a number of patent applications (see, for example, WO 95/35309 , WO 96/178860, WO 96/24609, WO 96/25426, WO 98/06741, WO 98/09950.
  • Scheme II describes an alternative way of preparing the compounds I by a convergent synthesis.
  • the appropriately protected building blocks P-D-E-OH and H-G-K-L * are coupled together, the resulting intermediate product P-D-E-G-K-L * in
  • Boc, Cbz or F oc are used as N-terminal protective groups
  • C-terminal protective groups are methyl, tert-butyl and benzyl ester.
  • Amidine protecting groups are preferably BOC, Cbz and groups derived therefrom for solid phase synthesis. If the intermediate products contain olefinic double bonds, protective groups which are split off by hydrogenolysis are unsuitable.
  • Boc protective groups are removed hydrogenolytically by means of dioxane / HCl or TFA / DCM, Cbz protective groups or with HF, Fmoc protective groups with piperidine.
  • the saponification of ester functions takes place with LiOH in an alcoholic solvent or in dioxane / water.
  • t-Butyl esters are cleaved with TFA or dioxane / HCl.
  • Reversed phase HPLC separations were carried out with acetonitrile / water and HOAc buffer.
  • the starting compounds can be prepared using the following methods: AB blocks:
  • A-B building blocks are commercially available sugar derivatives.
  • protective groups are introduced at the necessary points.
  • functional groups are converted into reactive or leaving groups (e.g. cabonic acids into active esters, mixed anhydrides, etc.) in order to enable a corresponding chemical link with the 10 other building blocks.
  • the aldehyde or keto function of the sugar derivatives can be used directly for the reductive alkylation with the terminal N atom of the D or E building block.
  • the D building blocks 4-aminocyclohexane carboxylic acid, 4-aminobenzoic acid, 4-aminomethylbenzoic acid, 4-aminomethylphenylacetic acid and 4-aminophenylacetic acid can be purchased for 20.
  • the compounds glycine, (D) or 25 (L) -alanine, (D) or (L) -valin, (D) -phenylalanine, (D) -cyclohexyl-alanine, (D) -cycloheptylglycine, D-diphenylalanine, etc. are either commercially available as free amino acids, as Boc-protected compounds or as corresponding methyl esters.
  • Cycloheptylglycine and cyclopentylglycine were prepared by reacting cycloheptanone or cyclopentanone with ethyl isonitrile acetic ester in accordance with known regulations (H.-J. recupertorius, J. Flossdorf, M.Kula, Chem. Ber. 1985, 108, 3079 or U. Schöllkopf and R. Meyer, Liebigs Ann.CHem. 1977,
  • D-dicyclohexylalanine was prepared by hydrogenation in accordance with T.J. Tucker et al J. Med. Chem. 1997, 40, 3687-3693.
  • amino acids mentioned were provided with a protective group either at the N or at the C-terminal according to generally known processes.
  • Boc-2-aminomethyl-thiazole 4-carboxamide (75.0 g, 0.29 mol) were suspended in 524 ml of methylene chloride and treated at -5 to 0 ° C with triethylamine ( 78.9 g, 0.78 mol) and 79.5 g (0.38 mol) of trifluoroacetic anhydride were added. The mixture was stirred for 1 h, the mixture was allowed to warm to 20 to 25 ° C., 1190 ml of water were added and the phases were separated.
  • This compound was synthesized starting from 5-aminomethyl-3-cyanothiophene by reaction with (Boc) 2 0 to 5-t-butyl-oxycarbonyl-aminomethyl-3-cyanothiophene, conversion of the nitrile function into the corresponding thioamide by addition of hydrogen sulfide, methylation of the thioamide function with methyl iodide, reaction with ammonium acetate to the corresponding amidine and subsequent deprotection with hydrochloric acid in isopropanol to give 5-aminomethyl-3-amidino-thiophene bishydrochloride.
  • the representation of the HGK-CN building block is exemplary for prolyl-4-cyanobenzylamide in WO 95/35309, for 3,4-dehydroprolyl-4-cyanobenzylamide in WO 98/06740 and for 3,4-dehydroprolyl-5- (2-cyano ) -thienylmethylamide described in WO 98/06741.
  • the preparation of 3,4-dehydroprolyl-5- (3-cyano) -thienylmethylamide was carried out analogously by coupling Boc-3,4-dehydro-prolin with 5-aminomethyl-3-cyano-thiophene hydrochloride and subsequent deprotection.
  • HEGKC N0H
  • H- (D) -Chg-Pyr-NH-CH 2 - 5- (3-am) -thioph was analogous to H- (D) -Cha-Pyr-NH-CH 2 -2- (4-am) -thiaz
  • Example 6 (L) -Glycer- (D) -Cha-Pyr-NH-CH 2 -2- (4-am) -thiaz xCH 3 COOH This compound was prepared analogously to Example 1 starting from L- (+) -glyceraldehyde , ESI-MS: M + H + : 479
  • This compound was prepared analogously to Example 7 starting from D-melibiosis.
  • This compound was prepared analogously to Example 7 starting from D-glucose.
  • This compound was prepared analogously to Example 7 starting from maltohexaose.
  • This compound was prepared analogously to Example 7 starting from cellobiose.
  • This compound was prepared analogously to Example 7 starting from D-glucose.
  • This compound was prepared analogously to Example 7 starting from maltose.
  • Example 17 Malto- (D) -Cha-Pyr-NH-CH 2 -2- (4-ham) -thiaz
  • the thrombin time was determined according to Example A for the following compounds:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention concerne de nouvelles amidines et guanidines, leur production et leur utilisation en tant qu'inhibiteurs compétitifs de sérine-protéases de type trypsine, notamment de thrombine et des protéases du complément C1s et C1r. La présente invention a trait à des compositions pharmaceutiques qui contiennent lesdits composés en tant que qu'ingrédients actifs, ainsi qu'à l'utilisation desdits composés en tant qu'inhibiteurs de thrombine, qu'anticoagulants, qu'inhibiteurs du complément et en tant qu'agents anti-inflammatoires. Ces nouveaux composés sont caractérisés par la liaison d'un inhibiteur de sérine-protéases, présentant une fonction amidine ou guanidine, à un radical alkyle présentant deux ou plusieurs fonctions hydroxyle, ce radical alkyle dérivant de dérivés de sucre. On peut ainsi lier également plusieurs composants sucre ou composants dérivés de sucre les uns aux autres. Ce principe de liaison à des dérivés de sucre permet d'obtenir des composés actifs par voie orale.
EP01969785A 2000-10-06 2001-09-27 Inhibiteurs a faible poids moleculaire de serine-proteases presentant des radicaux polyhydroxyalkyle et polyhydroxycycloalkyle Ceased EP1370573A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10049937 2000-10-06
DE10049937A DE10049937A1 (de) 2000-10-06 2000-10-06 Niedermolekulare Inhibitoren von Serinproteasen mit Polyhydroxyalkyl- und Polyhydroxycycloalkylresten
PCT/EP2001/011207 WO2002030940A2 (fr) 2000-10-06 2001-09-27 Inhibiteurs a faible poids moleculaire de serine-proteases presentant des radicaux polyhydroxyalkyle et polyhydroxycycloalkyle

Publications (1)

Publication Number Publication Date
EP1370573A2 true EP1370573A2 (fr) 2003-12-17

Family

ID=7659136

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01969785A Ceased EP1370573A2 (fr) 2000-10-06 2001-09-27 Inhibiteurs a faible poids moleculaire de serine-proteases presentant des radicaux polyhydroxyalkyle et polyhydroxycycloalkyle

Country Status (9)

Country Link
US (3) US20040048815A1 (fr)
EP (1) EP1370573A2 (fr)
JP (1) JP2004511489A (fr)
AR (1) AR036326A1 (fr)
AU (1) AU2001289932A1 (fr)
CA (1) CA2424926A1 (fr)
DE (1) DE10049937A1 (fr)
MX (1) MXPA03002923A (fr)
WO (1) WO2002030940A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10259382A1 (de) * 2002-12-18 2004-07-01 Abbott Gmbh & Co. Kg 3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-4-on-Derivate, ihre Herstellung und Verwendung
EP3852820B1 (fr) 2018-09-17 2024-11-20 Board of Regents, The University of Texas System Compositions et procédés de traitement d'une lésion osseuse

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4115468A1 (de) * 1991-05-11 1992-11-12 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien
DE4206858A1 (de) * 1992-03-05 1993-09-09 Behringwerke Ag Glycopeptid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische mittel
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
DE4421052A1 (de) * 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
DE4443390A1 (de) * 1994-12-06 1996-06-13 Basf Ag Neue dipeptidische p-Amidinobenzylamide mit N-terminalen Sulfonyl- bzw. Aminosulfonylresten
FI973282L (fi) * 1995-02-10 1997-08-08 Basf Ag Trombiinin inhibiittoreita
US6030972A (en) * 1995-02-17 2000-02-29 Basf Aktiengesellschaft Dipeptide amidines as thrombin inhibitors
CN1121384C (zh) * 1995-07-26 2003-09-17 三菱化学株式会社 青霉胺酰胺衍生物
DE19632773A1 (de) * 1996-08-14 1998-02-19 Basf Ag Neue Thrombininhibitoren
DE19632772A1 (de) * 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
WO1999065934A1 (fr) * 1998-06-17 1999-12-23 Akzo Nobel N.V. Composes antithrombotiques
KR20000047461A (ko) * 1998-12-29 2000-07-25 성재갑 트롬빈 억제제

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0230940A2 *

Also Published As

Publication number Publication date
US20120190832A1 (en) 2012-07-26
AR036326A1 (es) 2004-09-01
WO2002030940A3 (fr) 2003-10-02
AU2001289932A1 (en) 2002-04-22
MXPA03002923A (es) 2003-08-07
DE10049937A1 (de) 2002-04-11
US20040048815A1 (en) 2004-03-11
JP2004511489A (ja) 2004-04-15
CA2424926A1 (fr) 2003-04-04
US20110071285A1 (en) 2011-03-24
WO2002030940A2 (fr) 2002-04-18

Similar Documents

Publication Publication Date Title
DE69620161T2 (de) Thrombininhibitoren
EP1169338A2 (fr) Inhibiteurs de faible poids moleculaire des proteases du complement
DE69620165T2 (de) Piperazinone als inhibitoren von blutplattchenaggregation
JPH07505876A (ja) エラスターゼ阻害剤としてのピリミジニルアセトアミド
EP1272458B1 (fr) Mimetiques de l'arginine utilises comme inhibiteurs du facteur xa
EP1114024B1 (fr) Inhibiteurs de l'urokinase
EP0508220B1 (fr) Dérivées d'amidino-phenylalanine, procédé de leur préparation, leur utilisation et composition les contenants
DE10029014A1 (de) Urokinase-Hemmstoffe
JPS63152388A (ja) 新規なセフェム化合物
DE69315699T2 (de) Inhibitoren gegen die aggregation von blutplättchen
DE4443390A1 (de) Neue dipeptidische p-Amidinobenzylamide mit N-terminalen Sulfonyl- bzw. Aminosulfonylresten
EP1165601A2 (fr) Promedicaments d'inhibiteurs de la thrombine
EP1051431A1 (fr) Inhibiteurs de la thrombine
DE69426897T2 (de) Antithrombotisch wirkende azacycloalkyl-alkanoyl-peptide und-pseudopeptide
DE10029015A1 (de) Hemmstoffe für den Gerinnungsfaktor Xa
DE60126046T2 (de) Bizyklische Amino-Pyrazon Derivate, deren Herstellung und pharmazeutische Zusammensetzungen
WO1999037611A1 (fr) Amidines heterocycliques utilisees comme inhibiteurs de la kallicreine
DE10210590A1 (de) Hemmstoffe des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
EP1370573A2 (fr) Inhibiteurs a faible poids moleculaire de serine-proteases presentant des radicaux polyhydroxyalkyle et polyhydroxycycloalkyle
DE69908756T2 (de) Matrix-metalloproteinase-inhibitoren
EP0486702A1 (fr) Derive de 4-guanidinobenzoate de phenyle, procede de production dudit derive et inhibiteur de protease contenant ledit derive
DE60010344T2 (de) Diketopiperazinderivate als thrombininhibitoren
EP1169318A1 (fr) Promedicaments d'inhibiteurs de la thrombine
DE19504504A1 (de) Heterocyclische Thrombininhibitoren
JPH08325229A (ja) 新規なω−グアニジノ−Ｌ−α−アミノ酸アミド誘導体

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030414

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20100423